Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096

Herantis Pharma announced positive FDA feedback on its Phase 2a study design for HER-096, a lead candidate for Parkinson's disease treatment. The company has finalized the study design to enroll approximately 100 patients and secured over 50% of Phase 2 funding. The FDA raised no concerns regarding chemistry, manufacturing, controls, or preclinical data, and confirmed readiness for U.S. clinical site activation.

06/02/2026, 7:00 AM • GlobeNewswire

What to Know About This Fund's $74.8 Million Indivior Sale

Divisadero Street Capital Management sold 2.26 million shares of Indivior (INDV) for approximately $74.76 million in Q1 2026, reducing its stake to 521,083 shares. The sale appears to be profit-taking after the stock surged nearly 200% over the past year. Despite the fund's exit, Indivior's fundamentals remain strong with Q1 revenue up 19% year-over-year to $317 million and SUBLOCADE sales jumping 32% to $232 million, prompting management to raise 2026 guidance.

05/30/2026, 4:01 PM • The Motley Fool

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Indivior presented new real-world data at the ASAM 2026 Annual Conference demonstrating that SUBLOCADE (monthly injectable buprenorphine) accounts for the smallest proportion of non-fatal and fatal overdose events compared to other medications for opioid use disorder. The company also presented findings from the ROUTE Study showing that remission from OUD correlates with improved quality of life, lower craving, and better functional outcomes beyond abstinence alone.

04/24/2026, 11:00 AM • GlobeNewswire

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

Indivior Pharmaceuticals (INDV) announced it will report first quarter 2026 financial results on April 30, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team. The company highlighted a cost impact model showing its monthly injectable buprenorphine treatment (SUBLOCADE) may reduce staffing burdens and costs in correctional facilities compared to other opioid use disorder medications.

04/09/2026, 7:00 AM • GlobeNewswire

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Pharmaceuticals priced a $450 million offering of 0.625% convertible senior notes due 2031, upsized from the initially announced $400 million. The notes have a conversion price of approximately $41.66 per share (35% premium to market price) and will mature on March 15, 2031. Net proceeds of approximately $437.7 million will be used to repay existing debt ($239 million plus $102 million cash on hand), repurchase approximately 2.4 million shares ($75 million), and fund general corporate purposes.

03/12/2026, 8:30 PM • GlobeNewswire

Indivior Announces Proposed Convertible Senior Notes Offering

Indivior Pharmaceuticals announced its intention to offer $400 million in convertible senior notes due 2031 in a private placement to qualified institutional buyers. The company plans to use approximately $239 million of net proceeds to repay existing term loan and revolving credit facility borrowings, up to $75 million for share repurchases, and the remainder for general corporate purposes. The notes will be convertible into common stock under specified conditions and redeemable after March 2029.

03/12/2026, 7:00 AM • GlobeNewswire

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

Indivior Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on February 26, 2026, followed by a leadership webcast. The company also completed its redomiciliation from the United Kingdom to the United States and provided 2026 financial guidance projecting total net revenue between $1,125-$1,195 million, with SUBLOCADE net revenue expected at $905-$945 million.

01/28/2026, 7:00 AM • GlobeNewswire

Here's Why Indivior Stock Soared 15% Today

Indivior reported strong Q3 results, upgrading full-year guidance for Sublocade sales to $825-$845 million. The company is executing a three-phase growth strategy focused on increasing U.S. sales and achieving expense savings.

10/30/2025, 2:18 PM • The Motley Fool

Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and Indivior

A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.

07/25/2025, 10:51 AM • GlobeNewswire